Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
- Author:
Hyung Joon YIM
1
;
Ji Hoon KIM
;
Jun Yong PARK
;
Eileen L. YOON
;
Hana PARK
;
Jung Hyun KWON
;
Dong Hyun SINN
;
Sae Hwan LEE
;
Jeong-Hoon LEE
;
Hyun Woong LEE
Author Information
- Publication Type:Review
- From:Clinical and Molecular Hepatology 2020;26(4):411-429
- CountryRepublic of Korea
- Language:0
- Abstract: Clinical practice guidelines are important for guiding the management of specific diseases by medical practitioners, trainees, and nurses. In some cases, the guidelines are utilized as a reference for health policymakers in controlling diseases with a large public impact. With this in mind, practice guidelines for the management of chronic hepatitis B (CHB) have been developed in the United States, Europe, and Asian-Pacific regions to suggest the best-fit recommendations for each social and medical circumstance. Recently, the Korean Association for the Study of the Liver published a revised version of its clinical practice guidelines for the management of CHB. The guidelines included updated information based on newly available antiviral agents, the most recent opinion on the initiation and cessation of treatment, and updates for the management of drug resistance, partial virological response, and side effects. Additionally, CHB management in specific situations was comprehensively revised. This review compares the similarities and differences among the various practice guidelines to identify unmet needs and improve future recommendations.
